ATRX and central nervous system cancer: IDH1 mutations exhibit lower MET and FDG accumulation, consistent with our findings [7]. A previous study suggested that IDH1 mutations result in the activation of HIF-1α and the normalization of aerobic glycolysis, leading to reduced FDG uptake [7]. Moreover, gliomas with ATRX loss have been reported to have lower MET-PET T/N ratios than those with wildtype ATRX [9], similar to the findings of this study.